Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + chemotherapy + apatinib for perioperative pulmonary sarcomatoid carcinoma
ChiCTR2400086577Phase 2Recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Jul 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of adebrelimab, Rivoceranib, paclitaxel, cisplatin and carboplatin in lung sarcomatoid carcinoma (PSC), sponsored by Tianjin Medical University General Hospital. Primary endpoint: Pathological complete remission rate. Started Jul 2024; status: recruiting.
02
Drugs
adebrelimabRivoceranibpaclitaxelcisplatincarboplatin
03
Conditions
lung sarcomatoid carcinoma (PSC)
Beyond the preview
Go deeper on ChiCTR2400086577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086577.